Introduction: Cervical cancer constitutes a major public health challenge, both in terms of its morbidity and its financial burden on health systems and patients. This study aimed to assess the direct medical costs incurred by women diagnosed with cervical cancer and managed at the Institute Curie of Aristide Le Dantec Hospital in Dakar, as well as to identify the main cost drivers. Methodology: A retrospective, cross-sectional, descriptive and analytical study was conducted from January to April 2018, including 94 patients. Data were collected from medical records and entered into Microsoft Excel. Statistical analyses were performed using the Analysis module of SPSS version 18 (Statistical Package of Social Science). Results: Among the 94 patients included in the study, 67.0% were diagnosed at a locally advanced stage, 20.2% at an advanced stage, and 10.6% at an early stage. The majority of patients originated from outside Dakar. Squamous cell carcinoma accounted for 83% of cases. Stage IIb was the most frequently observed stage, and the mean delay between the onset of initial symptoms and the first oncology consultation was 6 months. The average duration of symptoms before consultation was 8.7 months. A combination of chemotherapy, radiotherapy and surgery was administered to 31 patients, chemotherapy alone to 32 patients, while 17 patients did not receive active treatment. The main cost drivers for both national and non-national patients were medical imaging and radiotherapy. The average direct medical cost of cervical cancer management was estimated at 371,804 FCFA per patient, with a standard deviation of 174,205 FCFA. Medical imaging represented the largest cost component, followed by the cost of radiotherapy. The annual mean costs of hospitalization and endoscopic examinations were significantly higher among patients diagnosed with adenocarcinoma or other histological types, with p-values of 0.035 and 0.04, respectively. Similarly, the annual mean costs of consultations, hospitalizations, and histopathological examinations were significantly higher among patients diagnosed at stages III and IV, with p-values of 0.046, 0.027, and 0.021, respectively. Conclusion: Primary and tertiary prevention strategies, based on the effective implementation of policies aimed at reducing risk factors and providing financial support to patients, represent the most effective approach to lowering the burden of cervical cancer morbidity.
| Published in | International Journal of Health Economics and Policy (Volume 10, Issue 4) |
| DOI | 10.11648/j.hep.20251004.14 |
| Page(s) | 185-193 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
Prevention, Costs, Cervical Cancer, Treatment
| [1] | Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, and col. Worldwide burden of cervical cancer in 2008. Ann Oncol. dec 2011; 22(12): 2675-86. |
| [2] | Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, and col. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020; 8(2): e191-203. |
| [3] | Kodio A. Prevalence of Human Papillomavirus Infection and Precancerous Lesions of the Cervix in Sikasso [Thesis]. USTTB; 2020 [cited march 21 2021]. Available from: |
| [4] | OMS Globocan 2020. The Global Cancer Observatory/Mars 2021. |
| [5] | OMS. Cervical Cancer as a Priority for Prevention... - Google Scholar. [cited october 10 2025]. Available from: |
| [6] | Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018; 143: 22-36. |
| [7] | Ben Gobrane H, Aounallah-Skhiri H, Oueslati F, Frikha H, Achour N, Hsairi M. Estimation of the Cost of Managing Invasive Cervical Cancer in Tunisia. 2009; 21(6): 561. |
| [8] | N’guessan K, Kouakou F, Loué V, Angoi V, Abauleth Y, Boni S. Cervical Cancer: Epidemiological Aspects and Management in African Settings. Mali Med. 2009; 24(3). |
| [9] | Harizi C, Bellali H, Hchaichi A, Hamzaoui A, Chahed MK. Cost estimation of medical care management of lung cancer in Tunisia. East Mediterr Health J. 1 oct 2018; 24(10): 988-93. |
| [10] | Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-86. |
| [11] | Hussard S. Radiotherapy of Cervical Squamous Cell Carcinomas at Dalal Jamm Hospital in 2019. |
| [12] | Hasiniatsy NRE, Ernestho-ghoud IM, Ralamboson SA, Rabarijaona LI, Rafaramino F. Management and Follow-up of Cervical Cancer: The Reality in Antananarivo, Madagascar. J Afr CancerAfrican J Cancer. 2014; 6(1): 40-6. |
| [13] | Errachdi A, Asabbane A, Epala BN, Hemmich M, Kabbali N, Kebdani T, et al. Advanced Cervical Cancer: Evolutionary and Prognostic Aspects. Moroccan Experience. Presse Médicale. 2014; 43(10): e257-64. |
| [14] | Mboup MB, Attempt to Explain the Delay in Management of Cervical Cancer at the Joliot-Curie Institute. Thèse UCAD. 2017; N 175. |
| [15] | Lankoande J, Sakande B, Ouedraogo A, Mrouedraogo C, Ouattara T. Le cancer du col utérin: Dans le service de gynécologie-obstétrique du Centre Hospitalier National Yalgado Ouedraogo de Ouagadougou (Burkina Faso) aspects épidémio-cliniques et anatomo-pathologiques. Médecine Afr Noire. 1998; 45(7): 442-5. |
| [16] | Abboud J, Attieh E, Germanos A. Invasive Cervical Cancer: Treatment Adapted According to Available Therapeutic Resources. J Gynécologie Obstétrique Biol Reprod. 1992; 21(1): 19-22. |
| [17] | Banza K, Kizonde J, Unga M, Muiach K, Kabila B, Kalenga MK. Cervical Cancer: Challenges in Management. Propos De. 1999; 40. |
| [18] | Ahmad Fuady, Didik Setiawan, Irène Man, Inge MCM de Kok, Iacopo Baussano Toward a Framework for Evaluating the Financial and Economic Burden of Cervical Cancer in Low- and Middle-Income Countries: A Systematic Review. JCO Glob Oncol. 2024; 10: e2400066. |
| [19] | Ji, L.; Chen, M.; Yao, L. Strategies to Eliminate Cervical Cancer in China. Front. Oncol. 2023; 13: 1105468. |
| [20] | Yating Huang, Dantao Zhang, Lihua Yin, Jianguo Zhao, Li Zhifeng, Jing Lu, Xiaoming Zhang, Chenggang Wu, Wei Wu Modeling the Health Impact and Cost-Effectiveness of a Combined HPV Vaccination and Cervical Cancer Screening Program among Schoolgirls in Guangdong Province in China. Enfants (Bâle). 2024; 11(1): 103. |
| [21] | Rose Slavkovsky, Emily Callen, Clint Pecenka, Miséricorde Mvundura Costs of Human Papillomavirus Vaccine Delivery in Low- and Middle-Income Countries: A Systematic Review. Vaccin. 2024; 42(6): 1200-1210. |
APA Style
Diop, M., Dione, M., Aguiar, M., Leye, M. M. M. (2025). Study of the Direct Medical Costs Incurred by Women Diagnosed with Cervical Cancer and Followed up at the Institute Curie of Aristide Le Dantec Hospital. International Journal of Health Economics and Policy, 10(4), 185-193. https://doi.org/10.11648/j.hep.20251004.14
ACS Style
Diop, M.; Dione, M.; Aguiar, M.; Leye, M. M. M. Study of the Direct Medical Costs Incurred by Women Diagnosed with Cervical Cancer and Followed up at the Institute Curie of Aristide Le Dantec Hospital. Int. J. Health Econ. Policy 2025, 10(4), 185-193. doi: 10.11648/j.hep.20251004.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.hep.20251004.14,
author = {Mbathio Diop and Magatte Dione and Morel Aguiar and Mamadou Makhtar Mbacké Leye},
title = {Study of the Direct Medical Costs Incurred by Women Diagnosed with Cervical Cancer and Followed up at the Institute Curie of Aristide Le Dantec Hospital},
journal = {International Journal of Health Economics and Policy},
volume = {10},
number = {4},
pages = {185-193},
doi = {10.11648/j.hep.20251004.14},
url = {https://doi.org/10.11648/j.hep.20251004.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.hep.20251004.14},
abstract = {Introduction: Cervical cancer constitutes a major public health challenge, both in terms of its morbidity and its financial burden on health systems and patients. This study aimed to assess the direct medical costs incurred by women diagnosed with cervical cancer and managed at the Institute Curie of Aristide Le Dantec Hospital in Dakar, as well as to identify the main cost drivers. Methodology: A retrospective, cross-sectional, descriptive and analytical study was conducted from January to April 2018, including 94 patients. Data were collected from medical records and entered into Microsoft Excel. Statistical analyses were performed using the Analysis module of SPSS version 18 (Statistical Package of Social Science). Results: Among the 94 patients included in the study, 67.0% were diagnosed at a locally advanced stage, 20.2% at an advanced stage, and 10.6% at an early stage. The majority of patients originated from outside Dakar. Squamous cell carcinoma accounted for 83% of cases. Stage IIb was the most frequently observed stage, and the mean delay between the onset of initial symptoms and the first oncology consultation was 6 months. The average duration of symptoms before consultation was 8.7 months. A combination of chemotherapy, radiotherapy and surgery was administered to 31 patients, chemotherapy alone to 32 patients, while 17 patients did not receive active treatment. The main cost drivers for both national and non-national patients were medical imaging and radiotherapy. The average direct medical cost of cervical cancer management was estimated at 371,804 FCFA per patient, with a standard deviation of 174,205 FCFA. Medical imaging represented the largest cost component, followed by the cost of radiotherapy. The annual mean costs of hospitalization and endoscopic examinations were significantly higher among patients diagnosed with adenocarcinoma or other histological types, with p-values of 0.035 and 0.04, respectively. Similarly, the annual mean costs of consultations, hospitalizations, and histopathological examinations were significantly higher among patients diagnosed at stages III and IV, with p-values of 0.046, 0.027, and 0.021, respectively. Conclusion: Primary and tertiary prevention strategies, based on the effective implementation of policies aimed at reducing risk factors and providing financial support to patients, represent the most effective approach to lowering the burden of cervical cancer morbidity.},
year = {2025}
}
TY - JOUR T1 - Study of the Direct Medical Costs Incurred by Women Diagnosed with Cervical Cancer and Followed up at the Institute Curie of Aristide Le Dantec Hospital AU - Mbathio Diop AU - Magatte Dione AU - Morel Aguiar AU - Mamadou Makhtar Mbacké Leye Y1 - 2025/12/20 PY - 2025 N1 - https://doi.org/10.11648/j.hep.20251004.14 DO - 10.11648/j.hep.20251004.14 T2 - International Journal of Health Economics and Policy JF - International Journal of Health Economics and Policy JO - International Journal of Health Economics and Policy SP - 185 EP - 193 PB - Science Publishing Group SN - 2578-9309 UR - https://doi.org/10.11648/j.hep.20251004.14 AB - Introduction: Cervical cancer constitutes a major public health challenge, both in terms of its morbidity and its financial burden on health systems and patients. This study aimed to assess the direct medical costs incurred by women diagnosed with cervical cancer and managed at the Institute Curie of Aristide Le Dantec Hospital in Dakar, as well as to identify the main cost drivers. Methodology: A retrospective, cross-sectional, descriptive and analytical study was conducted from January to April 2018, including 94 patients. Data were collected from medical records and entered into Microsoft Excel. Statistical analyses were performed using the Analysis module of SPSS version 18 (Statistical Package of Social Science). Results: Among the 94 patients included in the study, 67.0% were diagnosed at a locally advanced stage, 20.2% at an advanced stage, and 10.6% at an early stage. The majority of patients originated from outside Dakar. Squamous cell carcinoma accounted for 83% of cases. Stage IIb was the most frequently observed stage, and the mean delay between the onset of initial symptoms and the first oncology consultation was 6 months. The average duration of symptoms before consultation was 8.7 months. A combination of chemotherapy, radiotherapy and surgery was administered to 31 patients, chemotherapy alone to 32 patients, while 17 patients did not receive active treatment. The main cost drivers for both national and non-national patients were medical imaging and radiotherapy. The average direct medical cost of cervical cancer management was estimated at 371,804 FCFA per patient, with a standard deviation of 174,205 FCFA. Medical imaging represented the largest cost component, followed by the cost of radiotherapy. The annual mean costs of hospitalization and endoscopic examinations were significantly higher among patients diagnosed with adenocarcinoma or other histological types, with p-values of 0.035 and 0.04, respectively. Similarly, the annual mean costs of consultations, hospitalizations, and histopathological examinations were significantly higher among patients diagnosed at stages III and IV, with p-values of 0.046, 0.027, and 0.021, respectively. Conclusion: Primary and tertiary prevention strategies, based on the effective implementation of policies aimed at reducing risk factors and providing financial support to patients, represent the most effective approach to lowering the burden of cervical cancer morbidity. VL - 10 IS - 4 ER -
Department of Odonto-Stomatology, University Cheikh Anta Diop, Dakar, Senegal
Institute of Health and Development, University Cheikh Anta Diop, Dakar, Senegal
Department of Odonto-Stomatology, University Cheikh Anta Diop, Dakar, Senegal
Institute of Health and Development, University Cheikh Anta Diop, Dakar, Senegal
Information